Alterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy ...

Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib.

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced ...

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

[1] One factor influencing the duration of drug development is the Food and Drug ... with a focus on fast-track designation, priority review, accelerated approval, and orphan drug status.

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Quantum computing isn’t just a step forward. It’s a giant leap into the future. Unlike traditional computers bound by binary logic, quantum machines tap into the bizarre world of quantum mechanics, ...

NeuroVive is eligible for more frequent meetings and communication with the FDA during the development process, and feedback on each section of its filing. Fast Track status is reserved for drugs ...

Detailed price information for Nervgen Pharma Corp (NGEN-X) from The Globe and Mail including charting and trades.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...

Ever had that gut-wrenching moment thinking, “If only I’d bought Bitcoin back in the day”? It’s the classic case of hindsight ...